Literature DB >> 26899756

The Prognostic Impact of Tumor Volume in Patients with Clinical Stage IA Non-Small Cell Lung Cancer.

Tomoyoshi Takenaka1, Koji Yamazaki2, Naoko Miura2, Ryo Mori2, Sadanori Takeo2.   

Abstract

INTRODUCTION: Tumor volume promises to be an important factor for predicting the prognosis of patients with non-small cell lung cancer (NSCLC).
METHODS: A total of 255 patients who underwent curative surgical resection for clinical stage IA NSCLC were included. We performed semiautomated measurement of the whole tumor volume and the volume of the solid part (referred to as the solid part volume) from a volumetric analysis of chest three-dimensional computed tomography scans using the SYNAPSE VINCENT imaging software program (Fujifilm Medical, Tokyo, Japan). We evaluated the relationships among tumor size, tumor volume, and survival.
RESULTS: The mean whole tumor size, the ratio of the maximum diameter of consolidation to the maximum tumor diameter (CTR), the whole tumor volume, and the solid part volume were 20 mm (range 0-30 mm), 0.84 (range 0-1.0), 3080 mm(3) (range 123-17509 mm(3)), and 2032 mm(3) (0-12466 mm(3)), respectively. The receiver operating characteristic area under the curve for the whole tumor size, CTR, whole tumor volume, and solid part volume used to identify recurrence were 0.60, 0.68, 0.58, and 0.69, respectively. A univariate analysis revealed that the whole tumor size, CTR, whole tumor volume, and solid part volume were associated with disease-free survival (DFS). A multivariate analysis of these factors identified the solid part volume to be the only independent factor for the prediction of DFS.
CONCLUSIONS: The whole tumor volume and the solid part volume were associated with DFS. In particular, the solid part volume was a very useful factor for predicting prognosis in clinical stage IA NSCLC.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical stage IA; Non–small cell lung cancer; Surgical resection; Tumor volume; Volumetry

Mesh:

Year:  2016        PMID: 26899756     DOI: 10.1016/j.jtho.2016.02.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  Implication of total tumor size on the prognosis of patients with clinical stage IA lung adenocarcinomas appearing as part-solid nodules: Does only the solid portion size matter?

Authors:  Hyungjin Kim; Jin Mo Goo; Young Joo Suh; Chang Min Park; Young Tae Kim
Journal:  Eur Radiol       Date:  2018-08-21       Impact factor: 5.315

Review 2.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

3.  Prognostic value of tumor solid-part size and solid-part volume in patients with clinical stage I non-small cell lung cancer.

Authors:  Yoshihisa Shimada; Hideyuki Furumoto; Kentaro Imai; Ryuhei Masuno; Jun Matsubayashi; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

4.  Postoperative changes of the free pericardial fat pad for bronchial stump coverage.

Authors:  Takuya Nagashima; Hiroyuki Ito; Joji Samejima; Daiji Nemoto; Daisuke Eriguchi; Haruhiko Nakayama; Tetsukan Woo; Munetaka Masuda
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

5.  Tumor volume is more reliable to predict nodal metastasis in non-small cell lung cancer of 3.0 cm or less in the greatest tumor diameter.

Authors:  Bei Jia; Biao Chen; Hao Long; Tiehua Rong; Xiaodong Su
Journal:  World J Surg Oncol       Date:  2020-07-15       Impact factor: 2.754

6.  Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy.

Authors:  Xiaolong Tang; Qingsi He; Hui Qu; Guorui Sun; Jia Liu; Lei Gao; Jingbo Shi; Jianhong Ye; Yahang Liang
Journal:  BMC Cancer       Date:  2019-08-13       Impact factor: 4.430

7.  The utility of three-dimensional computed tomography for prediction of tumor invasiveness in clinical stage IA lung adenocarcinoma.

Authors:  Yohei Kawaguchi; Masayuki Nakao; Kenshiro Omura; Naoya Iwamoto; Hiroki Ozawa; Yasuto Kondo; Junji Ichinose; Yosuke Matsuura; Sakae Okumura; Mingyon Mun
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

8.  Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.

Authors:  Juan Jiménez-Sánchez; Jesús J Bosque; Germán A Jiménez Londoño; David Molina-García; Álvaro Martínez; Julián Pérez-Beteta; Carmen Ortega-Sabater; Antonio F Honguero Martínez; Ana M García Vicente; Gabriel F Calvo; Víctor M Pérez-García
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

9.  The Study of Tumor Volume as a Prognostic Factor in T Staging System for Non-Small Cell Lung Cancer: An Exploratory Study.

Authors:  Bei Jia; Xu Zhang; Yunxian Mo; Biao Chen; Hao Long; Tiehua Rong; Xiaodong Su
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  Efficacy of measuring the invasive diameter of lung adenocarcinoma using mediastinal window settings: A retrospective study.

Authors:  Tsuyoshi Uchida; Hirochika Matsubara; Yuichiro Onuki; Hiroyasu Matsuoka; Tomofumi Ichihara; Hiroyuki Nakajima
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.